Alexandria Real Estate Equities (ARE)
(Delayed Data from NYSE)
$119.00 USD
+2.70 (2.32%)
Updated May 31, 2024 04:00 PM ET
After-Market: $118.89 -0.11 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.00 USD
+2.70 (2.32%)
Updated May 31, 2024 04:00 PM ET
After-Market: $118.89 -0.11 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Founded in 1994, Alexandria Real Estate Equities, Inc. is a Pasadena, CA-based urban office real estate investment trust (REIT) with particular focus on collaborative life science, agtech and technology campuses. The company’s assets are located in the AAA innovation cluster locations of North America, with considerable market presence in Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. The company enjoys a solid 10-year historical occupancy rate of 96% at operating properties in North America.
Alexandria Real Estate (ARE) Down 2.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Alexandria Real Estate (ARE) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alexandria Real Estate Equities (ARE) Reports In-Line Q2 FFO
by Zacks Equity Research
Alexandria Real Estate Equities' (ARE) Q2 results reflect robust growth in same-property net operating income (NOI) and strong leasing metrics.
REIT Stocks Q2 Earnings Due on Jul 31: VRO, ARE, BRX & NRZ
by Zacks Equity Research
Despite a number of headwinds prevailing in the REIT space, many companies are anticipated to display impressive results, mirroring economic recovery.
Alexandria (ARE) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Solid demand, strong cash flow and decent balance-sheet position will likely drive Alexandria Real Estate Equities' (ARE) performance in Q2. Let's see if these can lead to an earnings beat.
Alexandria Real Estate (ARE) Announces Hike in Q2 Dividend
by Zacks Equity Research
Alexandria Real Estate Equities, Inc. (ARE) announced second-quarter 2017 cash dividend of 86 cents per share, marking a sequential rise of 4%.
Alexandria Real Estate Prices 6.1M Common Shares Offering
by Zacks Equity Research
Alexandria Real Estate Equities, Inc. (ARE) announced the pricing of public offering of 6.1 million common shares at $108.55 per share.
The Zacks Analyst Blog Highlights: GGP, UDR, Alexandria Real Estate Equities and CBRE Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GGP, UDR, Alexandria Real Estate Equities and CBRE Group
Alexandria Real Estate, Merck Ink Long-Term Pharma Lease
by Zacks Equity Research
Alexandria Real Estate Equities, Inc. (ARE) has announced its tie up with Merck & Co., Inc. (MRK) to operate its new West Coast research facility.